Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Beneficial Effects of Pomegranate Extracts for Benign Gynecologic Disorders.

  • 2024-12-28
  • Reproductive sciences (Thousand Oaks, Calif.) 32(3)
    • Samya El Sayed
    • Valeria I Macri
    • Bhuchitra Singh
    • James H Segars
    • Md Soriful Islam

Study Design

Type
Review
Population
women with polycystic ovary syndrome; women in general for menopause quality of life; pre-clinical murine model following ovariectomy
Pomegranate (Punica granatum) is a widely cultivated fruit historically recognized for its health benefits and is regarded as a nutritional powerhouse. Pomegranate has a unique composition of bioactive compounds including hydrolysable tannins, anthocyanins, and other polyphenolic components. Of those, punicalagin and its subsequent metabolites are the most extensively studied, demonstrating antioxidant, anti-inflammatory, anti-cancer, and anti-nociceptive activity. The compounds possess promising therapeutic potential for many diseases, including conditions affecting the female reproductive system. This scoping review examines the pharmacodynamics of pomegranate's bioactive compounds and synthesizes the current literature concerning the role in benign gynecological disorders. Pomegranate extract decreased testosterone levels, levels of oxidative stress and inflammation biomarkers in women with polycystic ovary syndrome, erstwhile favorably impacting some cardiovascular risk factors in women. Pomegranate supplementation improved menopause specific health-related quality of life in women. In a pre-clinical murine model following ovariectomy, improved bone formation and reduced vaginal atrophy were associated with pomegranate treatment. Existing data suggests that additional research on the beneficial antioxidant, anti-inflammatory, anti-proliferative, and anti-nociceptive effects of pomegranate extracts for benign gynecologic conditions is warranted.

Research Insights

Back to top